Shigeki J. Miyake-Stoner

Shigeki J. Miyake-Stoner

Auto-generated profile, based on publicly available information

Shigeki J. Miyake-Stoner

Replicate Bioscience, Inc., San Diego, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2022 in Cancer Gene Therapy
Verified
Journal Article
Open access
PDF file
PAParinaz Aliahmad
Parinaz Aliahmad
SMShigeki J. Miyake-Stoner
Shigeki J. Miyake-Stoner
AGAndrew J. Geall
Andrew J. Geall
NWNathaniel S. Wang
Nathaniel S. Wang
RNA technology has recently come to the forefront of innovative medicines and is being explored for a wide range of therapies, including prophylactic and therapeutic vaccines, biotherapeutic protein expression and gene therapy. In addition to conventional mRNA platforms now approved for prophylactic SARS-CoV2 vaccines, synthetic self-replicating RNA vaccines are currently being evaluated in the clinic for infectious disease and oncology. The prototypical srRNA vectors in clinical development are derived from alphaviruses, specifically Venezuelan Equine Encephalitis Virus (VEEV). While non-VEEV alphaviral strains have been explored as single cycle viral particles, their use as synthetic vectors largely remains under-utilized in clinical applications. Here we describe the potential commonalities and differences in synthetic alphaviral srRNA vectors in host cell interactions, immunogenicity, cellular delivery, and cargo expression. Thus, unlike the current thinking that VEEV-based srRNA is a one-size-fits-all platform, we argue that a new drug development approach leveraging panels of customizable, synthetic srRNA vectors will be required for clinical success.